REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient ...
Motixafortide alone and in combination with natalizumab (VLA-4 inhibitor) led to robust hematopoietic stem cell (HSC) mobilization predicting 16.9 million and 19.6 million cells/kg collected in a ...
Stem cell mobilization and transplantation represent pivotal advances in the management of multiple myeloma. This therapeutic approach involves stimulating the release of haematopoietic stem cells ...
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced the publication ...
Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor We sought to evaluate PBSC ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results